YMI024 for coronary artery disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 18 Sep 2026: Trial started, NCT07830719
  2. 21 Sep 2026: Trial registered, NCT07830719

The trials

NCT07830719: Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP

State
Under way
Phase
Phase 2
People
180 planned
Started
18 Sep 2026
Primary completion
15 Aug 2027
Arms
YMI024 Dose 1, YMI024 Dose 2, YMI024 Dose 3, YMI024 Dose 4, YMI024 Dose 5
Results
None posted
  1. 18 Sep 2026: Trial started
  2. 21 Sep 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.